Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations

被引：0
|
作者：
S Simoens
I Huys
机构：
[1] KU Leuven Department of Pharmaceutical and Pharmacological Sciences,
来源：
Gene Therapy | 2017年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：539 / 541
页数：2
相关论文
共 28 条
  • [1] Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations
    Simoens, S.
    Huys, I.
    [J]. GENE THERAPY, 2017, 24 (09) : 539 - 541
  • [2] Nusinersen (Spinraza) for Spinal Muscular Atrophy
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1517): : 50 - 52
  • [3] Nusinersen for spinal muscular atrophy - results of an expanded access programme
    Mazurkiewicz-Beldzinska, Maria
    Kotulska-Jozwiak, Katarzyna
    Kopyta, Ilona
    Modrzejewska, Sandra
    Emich-Widera, Ewa
    Tomaszek, Katarzyna
    Paprocka, Justyna
    Chmielewski, Dariusz
    Pilch, Jacek
    Pietruszewski, Jerzy
    Lemska, Anna
    [J]. NEUROLOGY, 2019, 92 (15)
  • [4] Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy
    Pacione, Michelle
    Siskind, Carly E.
    Day, John W.
    Tabor, Holly K.
    [J]. JOURNAL OF NEUROMUSCULAR DISEASES, 2019, 6 (01) : 119 - 131
  • [5] Development of the Method for Nusinersen and Its Metabolites Identification in the Serum Samples of Children Treated with Spinraza for Spinal Muscular Atrophy
    Studzinska, Sylwia
    Mazurkiewicz-Beldzinska, Maria
    Buszewski, Boguslaw
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (17)
  • [6] Cytochemical Characterization of Cerebrospinal Fluid Macrophage Inclusions in Pediatric Patients Receiving Intrathecal Nusinersen (SPINRAZA®) for Spinal Muscular Atrophy
    Schafernak, Kristian T.
    Jacobsen, Jeffrey R.
    Hernandez, Dulce
    Kaye, Robin D.
    Perez, Sylvia E.
    [J]. ACTA CYTOLOGICA, 2022, 66 (01) : 79 - 84
  • [7] Cervical Puncture to Deliver Nusinersen in Patients with Spinal Muscular Atrophy and no Lumbar Access
    Veerapandiyan, Aravindhan
    Pal, Ria
    DAmbrosio, Stephen
    Young, Iris
    Eichinger, Katy
    Collins, Erin
    Westesson, Per-Lennart
    Kwon, Jennifer
    Ciafaloni, Emma
    [J]. NEUROLOGY, 2018, 90
  • [8] Transforaminal Intrathecal Access for Injection of Nusinersen in Adult and Pediatric Patients with Spinal Muscular Atrophy
    Shokuhfar, Tahaamin
    Abdalla, Ramez N.
    Hurley, Michael C.
    Nazari, Pouya
    Ansari, Sameer A.
    Ajroud-Driss, Senda
    Kuntz, Nancy
    Azmi, Subhan
    Rao, Vamshi
    Shaibani, Ali
    [J]. JOURNAL OF PEDIATRIC NEUROLOGY, 2020, 18 (02) : 88 - 94
  • [9] First experience of Nusinersen early access program in patients with spinal muscular atrophy type 1
    Gargaun, E.
    Aragon-Gawinska, K.
    Seferian, A.
    Gidaro, T.
    Gilabert, S.
    Lilien, C.
    Colcer, A.
    Boukouti, K.
    Vuillerot, C.
    Cances, C.
    Daron, A.
    Annousamy, M.
    De, A.
    Berliac, L. Flet
    Armier, H.
    Fiedler, L.
    Servais, L.
    [J]. NEUROMUSCULAR DISORDERS, 2017, 27 : S211 - S212
  • [10] Intellectual property rights, market competition and access to affordable antiretrovirals
    Pascual, Fernando
    [J]. ANTIVIRAL THERAPY, 2014, 19 : 57 - 67
123